Galmed Pharma (GLMD) Reports Phase 2 Data for Aramchol in Non-Alcoholic Steatohepatitis
Tweet Send to a Friend
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced today the oral abstract presentation of one-year results of the Company's global Phase 2b ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
